Celon Pharma Valuation

Q: What is the Fair Price of 0RKX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0RKX (PLN22.5) is trading below our estimate of [[fair value]] (PLN295.46)

Is 0RKX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Future Cash Flow Value
Significantly Below Future Cash Flow Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 0RKX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 0RKX (PLN22.5) is trading below our estimate of fair value (PLN295.46)

Significantly Below Future Cash Flow Value: 0RKX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RKX?

Key metric: As 0RKX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0RKX. This is calculated by dividing 0RKX's market cap by their current revenue.
What is 0RKX's PS Ratio?
PS Ratio	5.7x
Sales	zł215.11m
Market Cap	zł1.22b

0RKX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.5x
Enterprise Value/EBITDA	-62.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 0RKX's PS Ratio compare to its peers?

The above table shows the PS ratio for 0RKX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.6x
ANCR Animalcare Group	2.6x	5.16%	UK£228.9m
AGY Allergy Therapeutics	7.7x	n/a	UK£473.7m
EAH ECO Animal Health Group	0.7x	4.28%	UK£60.3m
HCM HUTCHMED (China)	3.3x	13.56%	UK£1.4b
0RKX Celon Pharma	5.7x	7.88%	zł1.2b

Price-To-Sales vs Peers: 0RKX is expensive based on its Price-To-Sales Ratio (5.7x) compared to the peer average (3.8x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 0RKX's PS Ratio compare vs other companies in the GB Pharmaceuticals Industry?

2 Companies	Price / Sales	Estimated Growth	Market Cap
HIK Hikma Pharmaceuticals	1.2x	4.55%	US$4.09b
EAH ECO Animal Health Group	0.7x	4.28%	US$79.81m

No more companies available in this PS range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 0RKX is expensive based on its Price-To-Sales Ratio (5.7x) compared to the European Pharmaceuticals industry average (3.7x).

Price to Sales Ratio vs Fair Ratio

What is 0RKX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RKX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	5.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0RKX's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

AnalystPriceTarget

Community Contributor

zł27.2

Fair Value

17.3% undervalued

Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/08/24 09:45
End of Day Share Price	2025/05/27 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Celon Pharma S.A. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Beata Szparaga-Wasniewska	Biuro maklerskie mBanku
Tomasz Sokolowski	Erste Bank Polska S.A.
Piotr Zielonka	Erste Bank Polska S.A.